KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rigel Pharmaceuticals (RIGL) Long-Term Debt Issuances (2022 - 2023)

Rigel Pharmaceuticals has reported Long-Term Debt Issuances over the past 2 years, most recently at $20.0 million for Q1 2023.

  • Quarterly results put Long-Term Debt Issuances at $20.0 million for Q1 2023, up 100.0% from a year ago — trailing twelve months through Dec 2023 was $20.0 million (up 2.09% YoY), and the annual figure for FY2023 was $20.0 million, up 2.09%.
  • Long-Term Debt Issuances for Q1 2023 was $20.0 million at Rigel Pharmaceuticals, up from $9.6 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for RIGL hit a ceiling of $20.0 million in Q1 2023 and a floor of -$33000.0 in Q2 2022.